These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 18815560

  • 1. Comments on "Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients".
    Schran HF, Hager DF.
    Pancreas; 2008 Oct; 37(3):334-5; author reply 336-7. PubMed ID: 18815560
    [No Abstract] [Full Text] [Related]

  • 2. Octreotide LAR in carcinoid: how to dose?
    Yao JC, Kvols LK.
    Pancreas; 2008 Oct; 37(3):337-8; author reply 338-9. PubMed ID: 18815562
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
    Khuroo MS, Khuroo MS, Khuroo NS.
    J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Two cases of thymic carcinoid treated with octreotide long-acting repeatable].
    Okabe N, Inoue T, Watanabe Y, Muto S, Hasegawa T, Ohsugi J, Higuchi M, Shio Y, Suzuki H.
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):879-83. PubMed ID: 25131876
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
    Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, Buscombe J, Caplin ME.
    Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Carcinoid and neuroendocrine tumors: building on success.
    Kunz PL.
    J Clin Oncol; 2015 Jun 01; 33(16):1855-63. PubMed ID: 25918282
    [Abstract] [Full Text] [Related]

  • 11. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
    Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, Corinaldesi R, Tomassetti P.
    Endocr Relat Cancer; 2008 Mar 01; 15(1):337-42. PubMed ID: 18310299
    [Abstract] [Full Text] [Related]

  • 12. Carcinoid tumor and intravenous octreotide infusion during labor and delivery.
    Le BT, Bharadwaj S, Malinow AM.
    Int J Obstet Anesth; 2009 Apr 01; 18(2):182-5. PubMed ID: 19200714
    [Abstract] [Full Text] [Related]

  • 13. Chromogranin A as a determinant of midgut carcinoid tumour volume.
    Kölby L, Bernhardt P, Swärd C, Johanson V, Ahlman H, Forssell-Aronsson E, Stridsberg M, Wängberg B, Nilsson O.
    Regul Pept; 2004 Aug 15; 120(1-3):269-73. PubMed ID: 15177946
    [Abstract] [Full Text] [Related]

  • 14. Is it time to widen the use of somatostatin analogs in neuroendocrine tumors?
    Oberg KE.
    J Clin Oncol; 2009 Oct 01; 27(28):4635-6. PubMed ID: 19704053
    [No Abstract] [Full Text] [Related]

  • 15. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period.
    Anthony L, Vinik AI.
    Pancreas; 2011 Oct 01; 40(7):987-94. PubMed ID: 21697761
    [Abstract] [Full Text] [Related]

  • 16. Octreotide scanning for carcinoid tumours.
    Critchley M.
    Postgrad Med J; 1997 Jul 01; 73(861):399-402. PubMed ID: 9338023
    [Abstract] [Full Text] [Related]

  • 17. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
    Pregun I, Gergics P, Dabasi G, Igaz P, Racz K, Tulassay Z.
    Eur J Gastroenterol Hepatol; 2009 Apr 01; 21(4):476-7. PubMed ID: 19382304
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.